Guardant Health has introduced a new version of its Guardant360 TissueNext test, identifying 498 genes in tumor tissue samples. The test will be offered to Medicare fee-for-service patients with advanced solid tumor cancers.
Key features of the product include expanded gene coverage of close to 500 biomarkers, compatibility with Guardant’s other genomic profiling tests, and operational workflow improvements for quicker results.
The company claims that the test can help oncologists make more informed decisions about treatment strategies and potentially boost patient outcomes by identifying a broader range of actionable biomarkers in tumor tissue.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.